152 related articles for article (PubMed ID: 36456154)
1. Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis.
Yi JH; Kim SJ; Lee JO; Lee GW; Kwak JY; Eom HS; Jo JC; Choi YS; Oh SY; Kim WS
Anticancer Res; 2022 Dec; 42(12):6083-6089. PubMed ID: 36456154
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.
Villa D; Sehn LH; Savage KJ; Toze CL; Song K; den Brok WD; Freeman CL; Scott DW; Gerrie AS
Blood Adv; 2020 Aug; 4(15):3486-3494. PubMed ID: 32735654
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
Murakami H; Yoshioka T; Moriyama T; Ishikawa T; Makita M; Sunami K
Acta Med Okayama; 2021 Aug; 75(4):461-469. PubMed ID: 34511613
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of bendamustine-rituximab combination therapy for newly diagnosed indolent B-cell non-Hodgkin's lymphoma and elderly mantle cell lymphoma: a multi-center prospective phase II clinical trial in China].
Wang H; He Q; Liu D; Deng XZ; Ma J; Xie LN; Sun ZL; Liu C; Zhao RR; Lu K; Chu XX; Gao N; Wei HC; Sun YH; Zhong YP; Xing LJ; Zhang HY; Zhang H; Xu WW; Li ZJ
Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):550-554. PubMed ID: 37749033
[No Abstract] [Full Text] [Related]
5. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
[TBL] [Abstract][Full Text] [Related]
6. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
8. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Flinn IW; van der Jagt R; Kahl B; Wood P; Hawkins T; MacDonald D; Simpson D; Kolibaba K; Issa S; Chang J; Trotman J; Hallman D; Chen L; Burke JM
J Clin Oncol; 2019 Apr; 37(12):984-991. PubMed ID: 30811293
[TBL] [Abstract][Full Text] [Related]
9. Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: A network meta-analysis.
Sheng Z; Wang L
Eur J Haematol; 2023 Jun; 110(6):602-607. PubMed ID: 36919283
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Matsumoto K; Takayama N; Aisa Y; Ueno H; Hagihara M; Watanabe K; Nakaya A; Chen K; Shimizu T; Tsukada Y; Yamada Y; Nakazato T; Ishida A; Miyakawa Y; Yokoyama K; Nakajima H; Masuda Y; Yano T; Okamoto S;
Int J Hematol; 2015 Jun; 101(6):554-62. PubMed ID: 25783753
[TBL] [Abstract][Full Text] [Related]
12. Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study.
Kotchetkov R; Drennan IR; Susman D; DiMaria E; Gerard L; Nay D; Prica A
Int J Cancer; 2023 May; 152(9):1884-1893. PubMed ID: 36545885
[TBL] [Abstract][Full Text] [Related]
13. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.
He JS; Chen X; Wei GQ; Sun J; Zheng WY; Shi JM; Wu WJ; Zhao Y; Zheng GF; Huang H; Cai Z
Medicine (Baltimore); 2019 Jan; 98(1):e13741. PubMed ID: 30608386
[TBL] [Abstract][Full Text] [Related]
14. Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma.
Bega G; Olivieri J; Riva M; Scapinello G; Paolini R; Finotto S; Sartori R; Lucchini E; Guandalini G; Facchinelli D; Tisi MC; Basso M; Ballotta L; Piazza F; Ferrarini I; Visco C
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885198
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
Lamonica D; Graf DA; Munteanu MC; Czuczman MS
J Nucl Med; 2017 Jan; 58(1):62-68. PubMed ID: 27469362
[TBL] [Abstract][Full Text] [Related]
16. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
17. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients].
Campbell J; Hurtado S; Kutz C; Soto K; Ernst D
Rev Med Chil; 2019; 147(1):9-17. PubMed ID: 30848759
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of
Zhang Y; He D; He J; Huang W; Yang Y; Cai Z; Zhao Y
Comput Math Methods Med; 2022; 2022():1080879. PubMed ID: 35096126
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience.
García-Noblejas A; Martínez Chamorro C; Navarro Matilla B; Da Silva Rodriguez C; González-Lopez TJ; Oña Navarrete R; Ramírez Sánchez MJ; Martínez Barranco P; Sánchez Blanco JJ; Nicolás C; Pérez R; Sánchez González B; Ruedas López AM; Domingo-Domenech E; Panizo C; Macia S; Fernández-Fonseca E; Cannata-Ortiz J; Arranz R
Ann Hematol; 2014 Sep; 93(9):1551-8. PubMed ID: 24782117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
